Regulatory Approval Milestones. 4.1.1. Nestlé will pay the Company the following milestone payments within [**] days of the achievement of the relevant milestone event as described below: Milestone Event Milestone Payment [**] [**] [**] [**] [**] [**] [**] [**] Provided, however that in the event:
Regulatory Approval Milestones. The following payments (each, an "Approval Milestone Payment") shall be made on a one-time basis with respect to the first ghgh Product to achieve corresponding milestone event (each, an "Approval Milestone"), if and only if the Co-Funding Term is not in effect when such Approval Milestone is achieved.
Regulatory Approval Milestones. The following payments shall be payable once as specified in the table below, with respect to the first Monotherapy Regimen or Incyte Combination Regimen Developed by Incyte, its Affiliates, or sublicensees (excluding Collaborators) to achieve the corresponding Milestone (each, an “Approval Milestone”): Approval Milestone Payment (USD)
Regulatory Approval Milestones. Following the Effective Date and subject to Section 11.8, in partial consideration of Scynexis’s grant of the rights and licenses to GSK hereunder, GSK shall pay to Scynexis, in accordance with the terms in this Section 6.3, the following one-time, non-refundable, non-creditable milestone payments (each, a “Regulatory Approval Milestone Payment”) upon the first achievement by or on behalf of GSK or any of its Affiliates or Sublicensees of the corresponding milestone event (each, a “Regulatory Approval Milestone Event”). Regulatory Approval Milestone Event Regulatory Approval Milestone Payment First NDA approval by the FDA for any Product [***] in the United States $[***] First MAA approval for any Product [***] (a) in at least [***] ([***]) of the following countries: [***] or (b) by the European Commission based on the recommendation by the EMA $[***] First JNDA approval by the PMDA for any Product [***] in Japan $[***] First NDA (or supplemental NDA) approval by the FDA for any Product [***] in the United States $[***] First NDA (or supplemental NDA) approval by the FDA for any Product [***] in the United States [***] $[***] First NDA (or supplemental NDA) approval by the FDA for any Product [***] in the United States [***] $[***] Total Regulatory Approval Milestone Payments: $70,000,000 For clarity, (i) each Regulatory Approval Milestone Payment shall be paid only one time, regardless of the number of Products, the number of Indications for which a Product is Commercialized, or the number of times a given Regulatory Approval Milestone Event has been achieved, and in no event will GSK be responsible for more than an aggregate of Seventy Million 52 Dollars ($70,000,000) in Regulatory Approval Milestone Payments and (ii) a single NDA Approval can trigger the achievement of one or more Regulatory Approval Milestone Events if the scope of such NDA Approval achieves the requirements of such Regulatory Approval Milestone Events and such Regulatory Approval Milestone Events have not been achieved prior to such NDA Approval. GSK shall notify Scynexis within [***] ([***]) following the first achievement of a given Regulatory Approval Milestone Event by GSK or any of its Affiliates or Sublicensees, and the corresponding Regulatory Approval Milestone Payment shall be due within [***] ([***]) after GSK’s receipt of a Valid Invoice in accordance with Section 6.7 for such Regulatory Approval Milestone Payment.
Regulatory Approval Milestones. Milestone Event (per Collaboration Target) Payment for BI Collaboration Projects Payment for Forma Collaboration Projects [***] [***] [***] [***] [***] [***] [***] [***] [***]
Regulatory Approval Milestones. Salix shall promptly inform Napo of the achievement of each of the milestones set forth below by Salix or any of its Affiliates or, if applicable, any of its Sublicensees. In partial consideration of the rights granted by Napo to Salix hereunder and subject to the terms and conditions set forth in this Agreement (including Sections 3.1 and 3.1.3 ), Salix shall pay to Napo a [*] milestone payment within [*] days after the achievement of each of the following milestones, calculated as follows: * Confidential treatment requested; certain information omitted and filed separately with the SEC.
Regulatory Approval Milestones. Pharvaris shall make to AnalytiCon the following one-time regulatory approval milestone payments: Milestone Event Amount (EUR) [*****] [***** ] [*****] [***** ]
Regulatory Approval Milestones. Affini-T shall notify to Metagenomi within [***] after the first achievement of each of the following Regulatory Approval milestone events with respect to each Affini-T Clinical Target once for each Field. Metagenomi shall submit an invoice for the applicable payment to Affini-T pursuant to Section 8.4.5(c) and Affini-T shall, within [***] of receipt of such invoice, make the following payments once for each Field, on an Affini-T Clinical Target-by-Affini-T Clinical Target basis (and corresponding to whether the Licensed Product achieving the relevant milestone is an Exclusively Licensed Product or a Non-Exclusively Licensed Product). Each Regulatory Approval milestone shall be payable only once for each Affini-T Clinical Target in each Field regardless of the number of Exclusively Licensed Products or Non-Exclusively Licensed Products associated with such Affini-T Clinical Target that achieve such milestone event. In the event a Licensed Product is directed to more than one Affini-T Clinical Target, such Licensed Product shall only trigger payment of applicable Regulatory Approval milestone amounts for a single Affini-T Clinical Target. Regulatory Approval Milestone Event in a Field Exclusively Licensed Product Milestone Payment ($ US Dollars) Non-Exclusively Licensed Product Milestone Payment ($ US Dollars) [***] [ ***] [ ***] [***] [ ***] [ ***] [***] [ ***] [ ***] Regulatory Approval Milestone Event in a Field Exclusively Licensed Product Milestone Payment ($ US Dollars) Non-Exclusively Licensed Product Milestone Payment ($ US Dollars) Maximum Total Regulatory Approval Milestone Payments $40,625,000 for each Affini-T Clinical Target if all Regulatory Approval Milestones were achieved by an Exclusively Licensed Product and a Non-Exclusively Licensed Product both directed to such Affini-T Clinical Target [***]
Regulatory Approval Milestones. Company shall pay Institution an aggregate fee of [REDACTED: Amount] in three (3) equal installments upon the first occurrence of each of the following regulatory approval milestones for the Product (each, a “Regulatory Milestone”, and each such amount, a “Regulatory Milestone Payment”):
Regulatory Approval Milestones. Novartis shall promptly notify Ophthotech in writing of the achievement of each regulatory approval milestone event below and Ophthotech shall issue an invoice for the corresponding milestone payment. Novartis shall make the corresponding non-refundable, non-creditable, one-time payment to Ophthotech set forth below in accordance with Section 7.06: Milestone Event Payment [**] $ [**] [**] $ [**] [**] $ [**] [**] $ [**]
